| Medical and Health Sciences | Lifetime | 386 | PL 1 | 99.98 |
| Medical and Health Sciences | 2021-2025 | 143 | PL 2 | 99.97 |
| Cardiology and Cardiovascular Medicine | Lifetime | 49 | PL 1 | 99.96 |
| Complementary and Alternative Medicine | Lifetime | 112 | PL 1 | 99.49 |
| Hematology | Lifetime | 206 | PL 1 | 98.83 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 434 | PL 2 | 98.69 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 29 | PL 1 | 99.90 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 66 | PL 1 | 99.05 |
| Hematology | 2021-2025 | 74 | PL 1 | 98.37 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 582 | PL 1 | 93.39 |
| Erythropoietin and Anemia Treatment | Lifetime | 1 | PL 1 | 99.86 |
| Heart Failure Treatment and Management | Lifetime | 7 | PL 1 | 99.95 |
| Cardiovascular Function and Risk Factors | Lifetime | 47 | PL 1 | 99.90 |
| Iron Metabolism and Disorders | Lifetime | 16 | PL 1 | 99.68 |
| Heart Rate Variability and Autonomic Control | Lifetime | 40 | PL 1 | 99.73 |
| Cardiovascular and exercise physiology | Lifetime | 53 | PL 1 | 99.61 |
| Cardiac pacing and defibrillation studies | Lifetime | 81 | PL 1 | 99.68 |
| Potassium and Related Disorders | Lifetime | 19 | PL 1 | 99.48 |
| Diabetes Treatment and Management | Lifetime | 190 | PL 1 | 99.22 |
| Electrolyte and hormonal disorders | Lifetime | 124 | PL 2 | 98.45 |
| Hemoglobinopathies and Related Disorders | Lifetime | 296 | PL 2 | 98.11 |
| Mechanical Circulatory Support Devices | Lifetime | 388 | PL 1 | 98.34 |
| Heart rate and cardiovascular health | Lifetime | 23 | PL 2 | 98.16 |
| Neuroscience of respiration and sleep | Lifetime | 508 | PL 2 | 97.96 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 844 | PL 5 | 98.07 |
| Cardiovascular Issues in Pregnancy | Lifetime | 416 | PL 1 | 96.81 |
| Obstructive Sleep Apnea Research | Lifetime | 645 | PL 4 | 96.35 |
| Cardiovascular Syncope and Autonomic Disorders | Lifetime | 836 | PL 4 | 93.50 |
| Pregnancy-related medical research | Lifetime | 614 | PL 1 | 93.71 |
| GDF15 and Related Biomarkers | Lifetime | 330 | PL 4 | 86.66 |
| Iron Metabolism and Disorders | 2021-2025 | 2 | PL 1 | 99.66 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 2 | PL 1 | 99.75 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 33 | PL 1 | 99.76 |
| Heart Failure Treatment and Management | 2021-2025 | 19 | PL 1 | 99.86 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 40 | PL 1 | 99.46 |
| Diabetes Treatment and Management | 2021-2025 | 59 | PL 1 | 99.38 |
| Electrolyte and hormonal disorders | 2021-2025 | 18 | PL 2 | 97.53 |
| Heart Rate Variability and Autonomic Control | 2021-2025 | 111 | PL 1 | 96.38 |
| Pancreatic function and diabetes | 2021-2025 | 128 | PL 1 | 97.40 |
| Potassium and Related Disorders | 2021-2025 | 26 | PL 1 | 97.74 |
| Hemoglobinopathies and Related Disorders | 2021-2025 | 152 | PL 1 | 95.79 |
| Cardiac Valve Diseases and Treatments | 2021-2025 | 657 | PL 2 | 95.85 |
| Mechanical Circulatory Support Devices | 2021-2025 | 953 | PL 3 | 89.96 |
| Renal function and acid-base balance | 2021-2025 | 102 | PL 4 | 85.49 |
| Cardiovascular and exercise physiology | 2021-2025 | 934 | PL 21 | 85.91 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 968 | PL 16 | 78.69 |
| Heart rate and cardiovascular health | 2021-2025 | 49 | PL 1 | 73.01 |
| Cardiac Fibrosis and Remodeling | 2021-2025 | 557 | PL 4 | 71.04 |
| GDF15 and Related Biomarkers | 2021-2025 | 282 | PL 1 | 69.37 |
| Cardiovascular Syncope and Autonomic Disorders | 2021-2025 | 677 | PL 10 | 70.62 |
| Signaling Pathways in Disease | 2021-2025 | 650 | PL 4 | 55.26 |
